Annual General Meeting of BioGaia
The Annual General Meeting of BioGaia AB (publ) on 6 May 2021 voted, among other things, to approve the following...
Read moreInterim Management Statement January – March 2021
First quarter 2021 · Net sales amounted to SEK 202.0 million (182.8), an increase of 10% (excluding foreign exchange...
Read moreBioGaia signs exclusive agreement in Egypt
BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The...
Read moreNotice to attend the Annual General Meeting of BioGaia AB (publ)
BioGaia AB (publ) will hold its Annual General Meeting on Thursday, 6 May 2021. In light of the coronavirus, the...
Read moreArticle about BioGaia in NutritionInsight
NutritionInsight has published an article based mainly on content from BioGaia’s recently published Annual report. The article mentions...
Read moreBioGaia publishes annual report for 2020
Today, BioGaia AB (publ) publishes its Annual Report, Remuneration rapport and Sustainability report for the financial year 2020. In line...
Read moreBioGaia Invest (BGI) – a new subsidiary focusing on innovative investments to support the growth of BioGaia
As part of BioGaia AB’s ambition to grow and develop as an innovative life science company, a separate entity,...
Read moreMetaboGen has reached a new crucial milestone in its development of novel probiotic products
MetaboGen aims at developing next generation probiotic products focusing on metabolic conditions with special emphasis on diabetes and related diseases....
Read more